Cataracts in Cancer Patients: At the Intersection of Oncology and Ophthalmology

Öz

Purpose: This study investigates the demographics, systemic diseases, and cataract types in cancer patients to improve clinical management. Methods: A retrospective case-control study was conducted on 330 cataract patients. Among them, half had both cataracts and cancer, while the other half had only cataracts. Demographic data, visual acuity, and systemic disease status were recorded. Cataracts were classified using LOCS III, and statistical analysis was performed with SPSS (p < 0.05). Results: The study included 165 cancer patients and 165 non-cancer patients with cataracts. Cancer patients were significantly younger (mean age: 61.63 ± 9.57 years) than non-cancer patients (mean age: 70.10 ± 6.09 years) (p = 0.01). Posterior subcapsular cataracts were more prevalent among cancer patients (55%), whereas nuclear cataracts were more frequent in the non-cancer group (37%). Systemic diseases were significantly more prevalent in the control group (76%) compared to cancer patients (60%) (p = 0.0021), with diabetes being the most common comorbidity in both groups. Conclusion: Cataracts develop at a significantly younger age in cancer patients compared to non-cancer patients, with posterior subcapsular cataracts being more prevalent in the cancer group. Cancer and its treatments may accelerate cataract formation. Regular ophthalmologic evaluations are crucial for the early detection and management of cataracts in cancer patients, ultimately enhancing their quality of life.

Anahtar Kelimeler

• Age-Related Cataract
• Neoplasms/complications
• Posterior Subcapsular Cataract

Destekleyen Kurum

This study received no funding from any institution or organization.

Etik Beyan

All procedures performed in this study were conducted in accordance with the Helsinki Declaration and relevant ethical guidelines. The study was approved by our Institutional Ethics Committee (Ethics Committee Approval No: 2022-03/61).

Teşekkür

The authors would like to express their gratitude to everyone who supported and contributed to this research. No specific individuals or organizations were acknowledged in this study.

Kanser Hastalarında Katarakt: Onkoloji ve Oftalmolojinin Kesişiminde

Öz

Amaç: Kanser hastalarında görülen kataraktın klinik özelliklerini incelemek ve kanser dışı katarakt hastaları ile karşılaştırmak. Gereç ve Yöntem: Retrospektif olgu-kontrol çalışmasına 165’i kanser hastası, 165’i ise kanser tanısı olmayan toplam 330 katarakt hastası dahil edildi. Demografik veriler, görme keskinliği ve sistemik hastalıklar kaydedildi. Kataraktlar LOCS III sınıflamasına göre değerlendirildi. İstatistiksel analizler SPSS programı ile yapıldı (p < 0.05). Bulgular: Kanser hastalarının yaş ortalaması, kanser dışı hastalardan anlamlı derecede düşüktü (61.63 ± 9.57 vs. 70.10 ± 6.09 yıl, p = 0.01). Kanser grubunda posterior subkapsüler katarakt daha sık görülürken (%55), kontrol grubunda nükleer katarakt daha yaygındı (%37). Sistemik hastalıklar kontrol grubunda daha yüksekti (%76 vs. %60, p = 0.0021). Her iki grupta da en sık komorbidite diyabetti. Sonuç: Kanser hastalarında kataraktlar daha erken yaşta gelişmekte ve posterior subkapsüler tip daha sık görülmektedir. Kanser ve tedavileri katarakt oluşumunu hızlandırabilir. Kataraktların erken tanı ve tedavisi için düzenli oftalmolojik takip önemlidir ve yaşam kalitesini artırabilir.

Anahtar Kelimeler

• Neoplazm/komplikasyon
• Posterior subkapsüler katarakt
• Yaşa bağlı katarakt.

Destekleyen Kurum

Bu çalışma herhangi bir kurum veya kuruluş tarafından desteklenmemiştir.

Etik Beyan

Bu çalışmada yer alan tüm işlemler, Helsinki Deklarasyonu ve ilgili etik kurallar çerçevesinde gerçekleştirilmiştir. Çalışma, kurumumuzun Etik Kurulu tarafından onaylanmıştır (Etik Kurul Onay 2022-03/61).

Teşekkür

Yazarlar, bu araştırmayı destekleyen ve katkıda bulunan herkese şükranlarını sunmak ister. Bu çalışmada özel olarak herhangi bir kişi veya kurum belirtilmemiştir.

Kaynakça

1. Jung H, Kim S, Kim BH, et al. Risks of cataract surgery in solid and hematologic cancer survivors. Sci Rep 2025;15:30263.
2. Muratov Y, Iztleuov Y, Aldasheva N, et al. Toxic effects of chemotherapy on the visual organ in malignant neoplasms: a systematic review. Georgian Med News 2025;(363):167-174.
3. Chodick G, Sigurdson AJ, Kleinerman RA, et al. The risk of cataract among survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Radiat Res 2016;185:366–374.
4. Chiang CC, Lin CL, Peng CL, Sung FC, Tsai YY. Increased risk of cancer in patients with early-onset cataracts: a nationwide population-based study. Cancer Sci 2014;105:431–436.
5. Sharma S, Lang C, Khadka J, Inacio MC. Association of age-related cataract with skin cancer in an Australian population. Invest Ophthalmol Vis Sci 2020;61:48.
6. Kulbay M, Wu KY, Nirwal GK, Bélanger P, Tran SD. Oxidative stress and cataract formation: evaluating the efficacy of antioxidant therapies. Biomolecules 2024;14(9):1055.
7. Yu-Chi L, Mark W, Terry K, et al. Cataracts. Lancet 2017;390:600–612.
8. Singh S, Pardhan S, Kulothungan V, et al. The prevalence and risk factors for cataract in rural and urban India. Indian J Ophthalmol 2019;67(4):477–483.

9. Hashemi H, Pakzad R, Yekta A, et al. Global and regional prevalence of age-related cataract: a comprehensive systematic review and meta-analysis. Eye (Lond) 2020;34(8):1357–1370.
10. Bayer A, Evereklioglu C, Demirkaya E, Altun S, Karslioglu Y, Sobaci G. Doxorubicin-induced cataract formation in rats and the inhibitory effects of hazelnut, a natural antioxidant: a histopathological study. Med Sci Monit 2005;11(8):BR300–304.
11. Akpek EK, Gottsch JD. Chemotherapy-induced ocular toxicity. Expert Opin Drug Saf 2024;23:455–468.
12. Yoon CI, Lee HS, Jeon S, Kim D, Park WC. Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea. Breast Cancer Res Treat 2023;197:603–612.
13. Jian YF, Zhang JS, Wan XH. Cataract induced by glucocorticoids. Clin Ophthalmol 2025;19:3703-3712.
14. Arturi FJ, Arons D, Murphy NJ, et al. The effects of radiation therapy on the ocular apparatus: implications for management. Cancers 2025;17(16):2605.
15. Kupfer C. Bowman lecture. The conquest of cataract: a global challenge. Trans Ophthalmol Soc UK 1985;104:1–10.
16. Varssano D, Friedman M, Goldstein M, et al. Association between cataract and keratinocytic skin cancers or melanoma: speculating on the common role of sun and ultraviolet radiation exposures. Ophthalmic Epidemiol 2017;24:336–340.
17. Beltrán-Zambrano E, García-Lozada D, Ibáñez-Pinilla E. Risk of cataract in smokers: a meta-analysis of observational studies. Arch Soc Esp Oftalmol (Engl Ed) 2019;94:60–74.
18. Kulkarni A, Banait S. Through the smoke: an in-depth review on cigarette smoking and its impact on ocular health. Cureus 2023;15(10):e47779.
19. Scherübl H. Tabakrauchen und Krebsrisiko (Tobacco smoking and cancer risk). Pneumologie 2023:27–32.
20. Valen H, Becher R, Vist GE, et al. A systematic review of cancer risk among users of smokeless tobacco (Swedish snus) exclusively, compared with no use of tobacco. Int J Cancer 2023;153(12):1942–1953.
21. Güvenç S, Akduran F. Cancers frequently encountered in Türkiye and worldwide and the role of nurses in cancer prevention. SAUHSD 2025;8(1):61–70.
22. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–263.
23. Özmen V. Breast cancer in Turkey: clinical and histopathological characteristics (analysis of 13,240 patients). J Breast Health 2014;10(2):98-105.
24. Akkus E, Tuncalı T, Akın HY, et al. Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases. Br J Haematol 2024;204(3):931-938.
25. Ataş M, Karatepe AS, Demircan S, Başkan B, Yüce Y, Zararsız G. The demographical characteristics and comorbidity of senile cataract patients in the central Anatolian region. Glo-Kat 2014;9:195–199.
26. Greenberg PB, Liu J, Wu WC. Predictors of mortality within 90 days of cataract surgery. Ophthalmology 2010;117:1894–1899.